Paper
Long-term survival in ovarian cancer: Mature data from The Netherlands joint study group for ovarian cancer

https://doi.org/10.1016/0277-5379(91)90011-2Get rights and content

Abstract

In two studies initiated in 1979 and 1981, 377 patients were treated for advanced epithelial ovarian cancer. In the first study patients were randomly assigned to receive Hexa-CAF (hexamethylmelamine, cyclophosphamide, methotrexate, 5-fluorouracil) or CHAP-5 (cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin for 5 days) and in the second study to receive CHAP-5 or CP (cyclophosphamide, cisplatin on 1 day). Patients who did not respond to Hexa-CAF were offered subsequent treatment that included cisplatin. Median follow-up of patients in the first study was 9.5 years and in the second study 7.7 years. At 10 years 9% of the patients initially treated with Hexa-CAF and 21% of patients assigned to CHAP-5 were alive. Among the 10-year survivors treated with Hexa-CAF, 50% had experienced progressive disease but were alive as a result of retreatment with a cisplatin regimen. The survival curves of both studies revealed that approximately 60% of the patients who reached a complete remission were alive at 5 years and 40% at 10 years. Patients with microscopic disease at second-look had a less favourable outlook: 35% survived 5 years. Not recognised at first publication of both studies was the influence of tumour grade on survival. Before 5 years of follow-up, the good prognosis of grade 1 tumours (well differentiated) could not be detected. About 50% of patients with grade 1 tumours were alive at 5 and 30% at 10 years while these survival rates were halved for the other grades. Combination chemotherapy with cisplatin can enhance survival by more than 10% at 5 and 10 years compared with the best treatment of the precisplatin era: Hexa-CAF.

References (6)

There are more references available in the full text version of this article.

Cited by (249)

  • Nanoemulsions for antitumor activity

    2022, Food, Medical, and Environmental Applications of Nanomaterials
  • The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period

    2016, Surgical Oncology
    Citation Excerpt :

    Once a diagnosis has been made, it is important to determine potential outcomes based on prognostic factors that will enable us to estimate the probability of recovery. In EOC, favorable independent predictors for 5-year overall survival (OS) include younger age, good performance status, histological type other than mucinous or clear cell, well-differentiated tumor grade, early stage, smaller tumor volume before surgical debulking, no residual tumor after debulking, and absence of ascites [11–16]. Close monitoring ensures that recurrence is readily identified and chemotherapy can be restarted in an attempt to turn the disease into a chronic process.

  • Why have ovarian cancer mortality rates declined? Part II. Case-fatality

    2015, Gynecologic Oncology
    Citation Excerpt :

    Across studies, median progression-free survival was about six months and median overall survival was about 12 months. After 10 years of follow-up, 95% of patients had progressed and 90% of patients had died [8,9]. Cisplatin was approved for the treatment of ovarian cancer in the United States in 1978.

  • Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study

    2009, Gynecologic Oncology
    Citation Excerpt :

    Epithelial ovarian cancer remains a leading cause of mortality from gynaecologic malignancies in Western countries, which mainly results from a late diagnosis [1-9].

View all citing articles on Scopus
View full text